Journal
ANNUAL REVIEW OF MICROBIOLOGY, VOL 73
Volume 73, Issue -, Pages 155-+Publisher
ANNUAL REVIEWS
DOI: 10.1146/annurev-micro-090817-062535
Keywords
phage therapy; antimicrobial resistance; antibiotic alternatives; lytic bacteriophage
Categories
Funding
- NATIONAL CANCER INSTITUTE [ZIABC010017] Funding Source: NIH RePORTER
Ask authors/readers for more resources
Burgeoning problems of antimicrobial resistance dictate that new solutions be developed to combat old foes. Use of lytic bacteriophages (phages) for the treatment of drug-resistant bacterial infections is one approach that has gained significant traction in recent years. Fueled by reports of experimental phage therapy cases with very positive patient outcomes, several early-stage clinical trials of therapeutic phage products have been launched in the United States. Eventual licensure enabling widespread access to phages is the goal; however, new paths to regulatory approval and mass-market distribution, distinct from those of small-molecule antibiotics, must be forged first. This review highlights unique aspects related to the clinical use of phages, including advantages to be reaped as well as challenges to be overcome.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available